-
Part 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
-
Part 5 | Session 1 Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers
-
Part 5 | Session 2 Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque
-
Part 5 | Session 4 Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers
-
Part 5 | Session 6 Dr Hahn: Innovative Areas of Cardiovascular Science in 2023
-
Part 5 | Session 7 Dr Forrest: Structural Heart Innovations and Advice to Young Researchers
-
Part 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen
-
Part 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti
-
Part 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial
-
Part 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI
-
Part 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study
-
Part 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients
-
Part 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF
-
Part 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure
-
Part 3 | Session 1 ACC.23 Late-breaking Science Wrap Up
-
Part 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview
-
Part 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos
Dr Harold Bays, Science Officer for the Obesity Medicine Association, member of the Board of Trustees of the Obesity Medicine Association, and member of the Board of Directors of the American Society of Preventive Cardiology joins us to talk about obesity management and the emergence of anti-obesity drugs and multidisciplinary team approach.
Discussion Points:
Unmeet Needs in the Management of Obesity
Available Strategies to Treat Obesity in 2023
Anti-obesity Medications
Definition of Success with Anti-obesity Medicines
Anti-obesity Drugs Compared to Bariatric Surgery
Multidisciplinary Team Approach
Takeaways for Cardiologists
Recorded on-site at ACC.23/WCC, New Orleans.
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Highlights Reviews
Faculty Biographies

Harold Bays
Medical Director and President
Dr Harold Bays is Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center, US. He has served as a Principal Investigator for over 600 clinical trials of metabolic therapeutic interventions.
Dr Bays is Board Certified in Internal Medicine and Endocrinology and Metabolism, Diplomate of the American Board of Obesity Medicine, and a Diplomate of the American Board of Clinical Lipidology. He is a Fellow of the Obesity Medicine Association, The Obesity Society, the American College of Cardiology, the American Association of Clinical Endocrinologists, the National Lipid Association, and the American Society of Preventive Cardiology.
Dr Bays has written or served as a contributing author to over 350 scientific manuscripts and book chapters and authored/presented 100’s of scientific abstracts.
Comments